Winthrop Advisory Group LLC Has $961,000 Position in Merck & Co., Inc. (NYSE:MRK)

Winthrop Advisory Group LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,410 shares of the company’s stock after selling 172 shares during the period. Winthrop Advisory Group LLC’s holdings in Merck & Co., Inc. were worth $961,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Itau Unibanco Holding S.A. bought a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $39,000. Abich Financial Wealth Management LLC lifted its stake in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after purchasing an additional 179 shares during the period. Quarry LP acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth approximately $42,000. Strategic Financial Concepts LLC increased its holdings in shares of Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after buying an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after buying an additional 122 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MRK. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating for the company in a report on Friday, November 1st. Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. Guggenheim reduced their price target on shares of Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating on the stock in a research report on Friday, November 1st. Finally, Truist Financial reduced their target price on shares of Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $129.80.

Merck & Co., Inc. Stock Up 0.5 %

Shares of MRK stock opened at $101.19 on Friday. The stock has a market cap of $256.30 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 1.46 and a beta of 0.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. Merck & Co., Inc. has a 52-week low of $98.60 and a 52-week high of $134.63. The firm’s 50-day moving average is $111.37 and its 200-day moving average is $120.33.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.07. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 37.32%. The firm had revenue of $16.66 billion for the quarter, compared to analysts’ expectations of $16.47 billion. During the same period in the prior year, the firm earned $2.13 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Sell-side analysts predict that Merck & Co., Inc. will post 7.76 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.